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Commentary (800 words starting from context and including references) 
Context 
Acute otitis media (AOM) is a leading cause of doctor consultations and antibiotic 
prescriptions in young children.1 Strategies to reduce antibiotic prescribing for AOM and 
thereby the emerging spread of antimicrobial resistance have focused on watchful 
waiting and delayed prescription, in particular in children over two years.2 An alternative 
strategy to combat antimicrobial resistance is to reduce the duration of antibiotic 
treatment. So far, the evidence to support this strategy in young children with AOM has 
been incomplete.3 
 
Methods 
Hoberman and colleagues recruited 520 children from an academic children’s hospital 
and affiliated paediatric practices and a private paediatric research practice in the US. 
Children were aged 6-23 months and diagnosed with AOM based on the following 
criteria: (i) recent onset of parent-reported AOM symptoms (score ≥3 on a 0-14 point 
scale), (ii) presence of middle ear effusion, and (iii) bulging of the tympanic membrane. 
Children were randomised to a 10-day course of amoxicillin-clavulanic acid (90/6.4mg/kg 
body weight) or a 5-day course followed by 5 days of placebo. The main outcome was 
the proportion of children who had clinical failure, defined as worsening or incomplete 
resolution of signs (primarily bulging of the tympanic membrane) and symptoms by the 
end of treatment at day 12-14. Secondary outcomes included symptom burden over 
days 6-14, the proportion of children whose symptom scores improved by at least 50% 
from baseline to end of treatment, AOM recurrence during the ongoing respiratory 
infection season, adverse events, nasopharyngeal colonization with penicillin-
nonsusceptible pathogens, healthcare resource use, and parental satisfaction with study 
treatment. Data were primarily analysed according to the intention-to-treat principle. 
 
Findings 
Clinical failure was more common in children who were treated with a 5-day course of 
amoxicillin-clavulanate than in those treated with a 10-day course: 77/229 (34%) versus 
39/238 (16%), respectively (difference 17%, 95% CI 9-25%, number needed to treat 
[NNT] = 6). Mean symptoms scores on the 0-14 point AOM symptom scale were 1.61 
versus 1.34 (p=0.07) over days 6-14 and 1.89 versus 1.20 (p=0.001) at the 12-14 day 
assessment for the 5- and 10-day course groups, respectively. At day 12-14, children 
treated with amoxicillin-clavulanate for 5 days were less likely to have symptom scores 
improved by at least 50% from baseline than those treated for 10 days: 181/227 (80%) 
versus 211/233 (91%) (p=0.003). There were no significant differences in other 
secondary outcomes. 
 
Commentary  
This well-designed and rigorously conducted non-inferiority trial provides important 
evidence on the effectiveness of a short- versus a long-course of antibiotics in young 
children with AOM. The study suggests that in young children with AOM a short (5 days) 
course is inferior to a standard (10 days) course; the between-group difference in clinical 
failure, a composite end-point of otoscopic findings and symptoms, did clearly exceed 
the pre-defined non-inferiority margin.  
 
The question remains, however, whether this difference means that all children aged 6-
23 months with AOM should be treated with antibiotics for 10 days. The difference in the 
outcome that matters most to parents and caregivers, i.e. ear pain, fever, sleeping and 
feeding problems, was at most small, and the majority of children had substantial 
improvement of symptoms by the end of treatment.4 This is consistent with the findings 
of a previous individual patient data meta-analysis of six trials (1643 patients) of 
antibiotics for AOM carried out in more economically developed countries, showing that 
even in children of this particular young age group, most cases of AOM resolve 
spontaneously.5 The benefit of antibiotics on symptoms was modest and most 
straightforward in children with bilateral AOM and in those presenting with acute ear 
discharge.5 
 
The rate of adverse events observed in the current trial is remarkable high, with one in 
three children reported as suffering from diarrhoea and dermatitis requiring a topical 
antifungal agent. This is important information for clinicians to share with parents and 
caregivers of young children when making decisions about antibiotic treatment. 
 
Implications for practice 
This high-quality trial improves the knowledge base for the management of childhood 
AOM. Based upon its findings, recommendations regarding the duration of antibiotic 
treatment in young children with AOM are unlikely to change. The high rate of resolution 
of symptoms in both groups and lack of effect of treatment duration on AOM recurrence, 
suggests that it is reasonable to advise parents to stop giving antibiotics after 5 days if 
AOM symptoms have resolved. 
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